Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura

Abstract Summary Treatment of acute immune thrombocytopenic purpura (ITP) with intravenous immunoglobulin (IVIG) induces partial or complete responses, shown by transient or persistent increases in platelet count. The clinical benefit could be due to blockade of the Fcγ receptor (FcγR); platelets sensitised by IgG could not be cleared by cells of the reticuloendothelial system if FcγR on these cells was blocked with IVIG. To find out whether this putative mechanism is correct, we treated twelve children who had acute ITP with intravenous infusions of Fcγ fragments. Eleven children showed rapid increases in platelet counts to above the critical value of 50 × 10 9 /L, thereby avoiding major haemorrhagic risk. The response was stable in six patients and transient in five. No adverse reactions were observed. In responders who had detectable platelet-associated IgG before treatment (> 1500 IgG per platelet), platelet IgG fell substantially with treatment. Serum soluble CD16 (sCD16 or sFcγRIII) concentrations, measured in five children, showed transient or stable increases that correlated with the rise in platelet count. No sCD16 was detected in the Fcγ preparation used. We conclude that the infusion of Fcγ fragments is an efficient treatment of acute ITP in children. The efficacy of Fcγ fragments strengthens the hypothesis that FcγR blockade is the main mechanism of action of IVIG in ITP, although other immunoregulatory mechanisms triggered by the presence of increased sCD16 concentrations in serum could be involved in the clinical benefit observed.

[1]  W. Fridman,et al.  Isotype regulation of antibody production: T-cell hybrids can be selectively induced to produce IgG1 and IgG2 subclass-specific suppressive immunoglobulin-binding factors. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Strong Le,et al.  Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. , 1946 .

[3]  C. Jacquillat,et al.  Soluble circulating Fc gamma receptors in human serum. A new ELISA assay for specific and quantitative detection. , 1987, Journal of immunological methods.

[4]  W. Fridman,et al.  Recombinant soluble receptors for the Fcγ portion inhibit antibody production in vitro , 1989 .

[5]  J. Oncley,et al.  The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma. , 1949, Journal of the American Chemical Society.

[6]  J. Bussel,et al.  Intravenous Treatment with Gammaglobulin in Adults with Immune Thrombocytopenic Purpura: Review of the Literature 1 , 1987, Vox sanguinis.

[7]  S. Burdach,et al.  Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: comparative efficacy of 7S and 5S preparations. , 1986, The Journal of pediatrics.

[8]  W. Fridman Structures and functions of low affinity Fc receptors , 1989 .

[9]  J. Fehr,et al.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. , 1982, The New England journal of medicine.

[10]  J. Muller,et al.  Evaluation des IgG fixées sur les plaquettes à l'aide d'un test utilisant une antiglobuline radio-active , 1983 .

[11]  W. Fridman,et al.  Production of an immunoglobulin-binding factor (IBF) by antigen-stimulated lymph node lymphocytes. , 1974, Journal of immunology.

[12]  W. Fridman,et al.  Fc receptors, immunoglobulin-binding factors and B chronic lymphocytic leukemia. , 1988, Nouvelle revue francaise d'hematologie.

[13]  W. Fridman,et al.  Involvement of FcR+ T cells and of IgG-BF in the control of myeloma cells. , 1990, Molecular immunology.

[14]  S. Wright,et al.  Human neutrophil Fc gamma receptor distribution and structure. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Salama,et al.  EFFECT OF INTRAVENOUS IMMUNOGLOBULIN IN IMMUNE THROMBOCYTOPENIA Competitive Inhibition of Reticuloendothelial System Function by Sequestration of Autologous Red Blood Cells? , 1983, The Lancet.

[16]  A. Hirt,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1981, The Lancet.

[17]  C. Rabourdin-Combe,et al.  Bases for an isotypic network. , 1986, Molecular immunology.

[18]  T. Huizinga,et al.  The Pi-linked receptor FcRIII is released on stimulation of neutrophils , 1988, Nature.

[19]  W. Fridman,et al.  Detection and quantification of secreted soluble FcγRIIA in human sera by an enzyme-linked immunosorbent assay , 1993 .

[20]  R. Kimberly,et al.  Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody , 1986 .

[21]  C. Anderson Structural and functional polymorphism of human Fc receptors for IgG. , 1989, Chemical immunology.

[22]  R. Testi,et al.  Membrane anchoring and spontaneous release of CD16 (FcR III) by natural killer cells and granulocytes , 1989, European journal of immunology.

[23]  J. Bernard,et al.  Treatment of adult autoimmune thrombocytopenic purpura with high-dose intravenous plasmin-cleaved gammaglobulins. , 2009, Scandinavian journal of haematology.

[24]  J. Bussel Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenic purpura. , 1989, The Journal of allergy and clinical immunology.

[25]  S. Kaveri,et al.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases , 1991, Clinical and experimental immunology.

[26]  F. Skvaril,et al.  Clinical Tolerance and Catabolism of Plasmin‐Treated γ‐Globulin for Intravenous Application , 1975 .

[27]  M. Dechavanne,et al.  Intravenous plasmin-treated gammaglobulin therapy in idiopathic thrombocytopenic purpura. Results in 40 patients. , 1985, Nouvelle revue francaise d'hematologie.